A Phase 2/3 interventional study of RELIEVA SPINPLUS® NAV Balloon Sinusplasty System in Chronic Maxillary Rhinosinusitis, sponsored by Cedars-Sinai Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-11.
Sponsored by Cedars-Sinai Medical Center · Phase 2/3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Rhinosinusitis with a site in United States — 11 open to participants now, 18 under way, 7 of them phase 3. Rhinosinusitis · United States.
Among the 71 studies in Rhinosinusitis with a site in United States, this one is the 33rd largest by planned enrollment of the 55 interventional ones that give a count, is one of 7 that started in 2024, is one of 3 in phase 2/3, reaches primary completion later than 13 of the 17 other live ones, and was the 57th registered.
252 studies on the registry are indexed under Rhinosinusitis; 70 are open to participants now.
Browse Rhinosinusitis studies →11 of the 71 studies in Rhinosinusitis with a site in United States are open now. Recruiting first, the newest first:
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Airiver Medical, Inc. · Sites in United States
Ages 18+
Optinose US Inc. · Sites in United States
Ages 12–17
The European Forum for Research and Education in Allergy and Airway Diseases · Sites in United States, Belgium, Canada and 8 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Argentina, Belgium and 17 more countries
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Rhinosinusitis studies recruiting now, 15 (44%) set no upper age limit and 13 (38%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 15 · Phase 4 12
First in 2003; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 74 across 177 interventional studies indexed under Rhinosinusitis.
Median enrollment 59 across the 55 interventional studies, 70 across the 16 observational. Of the 46 that completed or were terminated, 24 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 71 have an industry lead sponsor. The 10 most frequent:
Cedars-Sinai Medical Center is the lead sponsor of 457 studies on the registry; 108 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 49 (75%) have results posted.
Cedars-Sinai Medical Center has 1 study filed under Rhinosinusitis — fewer than ten, so there is no comparison to draw.
10 of the studies in Rhinosinusitis with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06706817Phase 3AstraZenecaA Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab | 2027-01-13 |
| NCT07424144Phase 3SanofiAn Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps | 2027-02-17 |
| NCT06338995Phase 3Eli Lilly and CompanyA Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) | 2027-05 |
| NCT06567821Phase 3Cedars-Sinai Medical CenterUsing Navigation to Improve Accuracy of Maxillary Balloon Sinusotomy | 2027-10-01 |
| NCT02038166University of Alabama at BirminghamNasal Potential Difference (NPD) Protocol in Chronic Rhinosinusitis | 2026-12 |
Add all 10 to your calendar (.ics) → With an account.
Among the 71 studies in Rhinosinusitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the research is to examine the effectiveness of navigation in maxillary sinus balloon dilation for the treatment of chronic maxillary rhinosinusitis.
The purpose of the research is to examine the effectiveness of navigation in maxillary sinus balloon dilation for the treatment of chronic maxillary rhinosinusitis. Adult patients (18 and over) with a confirmed diagnosis of chronic maxillary rhinosinusitis without nasal polyposis (CRSwNP) will undergo maxillary balloon sinusotomy. Block randomization will be performed to determine which side will receive balloon sinusotomy with navigation and which will have balloon sinusotomy using traditional anatomic landmarks. Participants will be followed for approximately 1 month post-procedure for a total study participation time of approximately 3 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The non-navigated device being used is the RELIEVA SPINPLUS® Balloon Sinusplasty System and the navigated device being used is the RELIEVA SPINPLUS® NAV Balloon Sinusplasty System. Both devices being used are standard devices that are currently FDA approved and used in practice for sinus dilation at Cedars-Sinai Medical Center.
Also known as: RELIEVA SPINPLUS® Balloon Sinusplasty System
Success Rate
There is a 30% expected improvement of success, in favor of navigation over non-navigation balloon sinuplasty devices.
Time frame: 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Oct 2027, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.